Courtney DiNardo, MD, Associate Professor at the University of Texas MD Anderson Cancer Center explains the results of a recent study assessing the safety and efficacy of venetoclax combination therapies in elderly patients with acute myeloid leukemia (AML).

AML is a rare blood cancer that tends to occur more often in the elderly. Standard chemotherapy for AML can be problematic in some elderly patients, especially those with other underlying conditions.

As Dr. DiNardo explains in this video, data presented at ASCO 2020 (Abstract 7531)  showed that over one-third of patients 75 and older who responded to therapy required at least two treatment rounds. Based on this data, it is advised that prior to discontinuing therapy for nonresponders, it is important to assess key predictive patient characteristics in the elderly.

For more information about AML and other rare cancers, visit

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.